



**Relationship of the number and size of superficial groin lymph nodes with the stage of secondary lymphatic edema**

Journal:	<i>Journal of Surgical Oncology</i>
Manuscript ID	JSO-2016-0650.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Onoda, Satoshi; University of Okayama, Plastic and Reconstructive Surgery Kimata, Yoshihiro; University of Okayama, Okayama Yamada, Kiyoshi; University of Okayama Seki, Noriko; University of Okayama Hiramatsu, Yuji; University of Okayama
Key Words:	superficial groin lymph nodes, lower limb lymphedema, secondary lymphedema, gynecologic cancer, risk factor

SCHOLARONE™  
Manuscripts

View

1  
2  
3  
4  
5 Relationship of the number and size of superficial groin lymph nodes  
6 with the stage of secondary lymphatic edema  
7

8 Short title/running head: Superficial groin lymph nodes  
9

10  
11 Satoshi Onoda<sup>1</sup> PhD, Yoshihiro Kimata<sup>1</sup> PhD, Kiyoshi Yamada<sup>1</sup> MD, Noriko Seki<sup>2</sup> PhD,  
12  
13 Yuji Hiramatsu<sup>2</sup> PhD  
14

15  
16 <sup>1</sup>Department of Plastic and Reconstructive Surgery, Graduate School of Medicine,  
17  
18 Dentistry and Pharmaceutical Science, University of Okayama, Okayama 700-8558,  
19  
20 Japan: E-mail: [satoshiprs18@gmail.com](mailto:satoshiprs18@gmail.com)  
21

22 <sup>2</sup>Department of Obstetrics and Gynecology, Graduate School of Medicine, Dentistry  
23  
24 and Pharmaceutical Science, University of Okayama, Okayama 700-8558, Japan  
25  
26

27  
28  
29 Correspondence to: Satoshi Onoda  
30

31 Department of Plastic and Reconstructive Surgery, Okayama University Graduate  
32  
33 School of Medicine, Dentistry and Pharmaceutical Science  
34  
35 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan  
36

37 Tel: +81-086-223-7151; Fax: +81-086-235-7210  
38

39 Email: [satoshiprs18@gmail.com](mailto:satoshiprs18@gmail.com)  
40  
41

42  
43  
44 Key words: superficial groin lymph nodes, lower limb lymphedema, secondary  
45  
46 lymphedema, gynecologic cancer, risk factor  
47

48  
49 Synopsis: We reviewed the relationship between the size, number, and laterality of  
50  
51 superficial groin lymph nodes and the staging and laterality of lower limb lymphedema  
52  
53 and reported that the size and number of superficial groin lymph nodes was a factor  
54  
55 associated with the development of lymphedema.  
56  
57  
58  
59  
60

## ABSTRACT

**Purpose:** This study evaluated the relationships of the size and number of superficial groin lymph nodes with the lower limb lymphedema stage and thus examined the role of superficial lymphatic lymph nodes in secondary lymphedema development.

**Methods:** We determined the number and size of superficial groin lymph nodes using horizontal plane computed tomography (CT) and the lymphedema stage in the lower limbs of 25 patients with gynecologic cancer.

**Results:** The patients had an average of 2.92 (range, 1–7) superficial groin lymph nodes; the mean size of the 146 evaluated lymph nodes was 7.55 mm (range, 5–15 mm). In 19 of 25 patients (76%), the side with major edema contained fewer superficial groin lymph nodes. In total, 22 patients (88%) had fewer superficial groin lymph nodes or a smaller total lymph node size on the edematous dominant side.

**Conclusions:** In this evaluation of the link between superficial groin lymph node laterality and secondary lymphedema staging, we found that patients with large lymph node numbers and sizes tended to present with a relatively earlier stage of lymphedema. Our results therefore suggest that the size and number of superficial groin lymph nodes affect the lymphedema stage.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Lymphedema can be classified roughly as primary lymphedema, which occurs without a particular cause, and secondary lymphedema, which is consequent to lymphadenectomy during malignant tumor resection, infection, or trauma.<sup>1-3</sup> Lymphedema can occur in various regions of the body, including the upper limbs,<sup>4-8</sup> lower limbs,<sup>9-10</sup> external genitalia,<sup>11</sup> lower abdomen, and head and neck region.<sup>12</sup> However, most cases of secondary upper limb lymphedema are attributed to axillary lymphadenectomy during breast cancer resection<sup>13-15</sup>, whereas most cases of lower limb lymphedema are attributed to pelvic lymphadenectomy during gynecologic or urologic cancer resection<sup>16-18</sup>.

Lymphatic flow can also be classified as superficial lymphatic flow, which occurs in the skin and subcutaneous fat tissue, and deep lymphatic flow, which occurs in the muscle and deep anatomic structures<sup>19-21</sup>; notably, previous studies have used lymphatic scintigraphy and indocyanine green fluorescence lymphography to demonstrate the former.<sup>22-24</sup> Generally, lymphatic drainage network reconstruction is assumed to occur via lymphatic neogenesis at the site of injury and at sites of other lymphatic outflow tracts that have been impeded by lymphadenectomy, infection, or injury. According to Kutuna, who conducted detailed examinations of lymphatic systems in a Japanese population, lymph flow in the lower limbs is refluxed through both superficial groin lymph nodes and the pelvic lymph nodes.<sup>25</sup> Scaglioni et al. further reported connections between the superficial and deep lymphatic system in the inguinal region. These findings suggest that superficial lymphatic flow in the groin plays an important role in the reconstruction of lymphatic circulation after malignant tumor resection with pelvic lymphadenectomy, as this procedure does not injure the superficial lymphatic flow.<sup>26-27</sup> To date, few reports have described the relationship between superficial lymphatic flow and secondary lymphedema. Accordingly, this study aimed to examine the role of superficial lymphatic circulation in the development of secondary lymphedema. Therefore, we reviewed the relationship between superficial groin lymph node laterality (i.e., non-equal number/size of lymph nodes in each limb) and lower limb lymphedema staging in patients with secondary lymphedema.

## MATERIALS AND METHODS

This study was performed under a protocol approved by the Okayama University Hospital ethics committee. Informed patient consent was deemed unnecessary for this study and was therefore not obtained. From January 2009 to June 2014, 373 patients with concerns regarding secondary lower limb lymphedema underwent follow-up evaluation at Okayama University Hospital. We retrospectively reviewed data of

1  
2  
3  
4  
5 patients who met the following selection criteria: history of gynecologic malignant  
6 tumor resection with pelvic lymph node dissection performed at our hospital, absence of  
7 superficial groin lymph node metastasis (determined using positron emission  
8 tomography), and a difference in lymphedema stage between the lower limbs.  
9 Regarding the latter factor, because the severity of cellulitis, prophylactic antibiotic use,  
10 radiotherapy dosage, chemotherapy, additional operative procedures for lymphedema  
11 (e.g., lymphaticovenular anastomosis) are considered factors affecting lymphedema  
12 staging, we decided to compare stage laterality within individual cases rather than  
13 differences in stage between individuals. A total of 25 patients were selected. For these  
14 patients, we evaluated the primary disease associated with lymphedema, cancer stage,  
15 bilateral lymphedema stage, history of chemotherapy and radiation therapy, and interval  
16 from the initial resection to lymphedema development (Table 1).

17  
18 In addition, we confirmed that pelvic lymph nodes were surgically resected and  
19 determined the metastatic positive rate and the sizes and number of superficial groin  
20 lymph nodes for each patient (Table 2). The number of pelvic lymph nodes resected  
21 during primary surgery was determined according to the postoperative pathological  
22 diagnosis. The number and sizes of superficial groin lymph nodes were determined  
23 using preoperative horizontal plane computed tomography (CT) images (Figures 1 and  
24 2). We defined superficial groin lymph nodes as those present in adipose tissue on the  
25 anterior surface of the fascia lata in the inguinal lower groin area (Figure 3) In addition,  
26 these nodes were larger than 5 mm, as preoperative CT was unable to identify smaller  
27 nodes (Figures 4 and 5).

28  
29 For lymphedema staging, we used the International Society of Lymphology  
30 classification. Stage was determined by examining clinical records and photographs  
31 obtained at the initial diagnosis (Table 3), and decisions were confirmed in consensus by  
32 three physicians. Regarding edema laterality, we defined the side with the higher stage  
33 as the dominant edema side, and the side with the lower stage as the inferior edema side.

#### 34 35 36 37 38 39 40 41 42 43 44 45 46 *Data analysis*

47 A two-sided Student's t test was used to evaluate differences of in the pelvic lymph  
48 nodes resected from the dominant and inferior edema sides. Chi-square analyses (with  
49 Fisher's transformation if necessary) were performed to evaluate the correlation of the  
50 presence or absence of lymph node metastases of the malignant tumor and the dominant  
51 edema side. A P value <0.05 was considered to indicate statistical significance.  
52 Furthermore, we calculated the correlation coefficient between the total size of the  
53 superficial groin lymph nodes and lower limb lymphedema staging to identify a  
54  
55  
56  
57  
58  
59  
60

potential statistical relationship between these factors.

## RESULTS

Patients in our study had the following primary disease diagnoses: cervical cancer, 15 patients; endometrial cancer, 9 patients; and endometrial and ovarian cancer, 1 patient. All patients underwent pelvic lymphadenectomy during primary tumor resection, and a mean of 2.92 (range, 1–7) superficial groin lymph nodes were removed from each of the 50 lower limbs of the patients. The mean size of the 146 resected lymph nodes was 7.23 mm (range, 5–12 mm). Regarding laterality, 16 patients exhibited right leg-dominant edema, whereas 9 patients exhibited left leg-dominant edema (Table 1). The mean numbers of pelvic lymph nodes resected from the dominant and inferior edema sides were 19.4 (range, 7–40) and 15.5 (range, 6–26), respectively. Sixteen and 18 metastatic lymph nodes were observed at the dominant and inferior edema sides, respectively, and the corresponding mean numbers of pelvic metastatic lymph nodes were 0.64 (range, 0–6) and 0.72 (range, 0–7), respectively. Notably, the sides did not differ significantly with respect to the resected pelvic lymph nodes ( $P = 0.5510$ ) or pelvic lymph node metastasis ( $P = 0.2890$ ); however, dominant edema side was found to contain fewer superficial groin lymph nodes in 19 of 25 patients (76%). Three (12%) of the remaining 6 patients had equal numbers of lymph nodes in both legs, although the sum total size of the superficial lymph nodes was smaller on the dominant edematous side. In total, 22 patients (88%) had either fewer superficial groin lymph nodes or a smaller total lymph node size on the dominant edema side. Using scatter plots, we determined a correlation coefficient between the sum total size of the superficial groin lymph nodes and the lymphedema stage of  $-0.2866$  (Figure 6). The mean interval from initial resection to lymphedema development was 17 months.

### *Representative case*

Seven years prior to our study, a 68-year-old woman had undergone radical hysterectomy with pelvic lymphadenectomy and postoperative radiotherapy for stage 2B cervical cancer; at this time, 2 superficial groin lymph nodes (7 and 8 mm) in the right groin and 5 nodes (7, 8, 8, 9, and 10 mm) in the left groin were detected via preoperative CT, and the case was designated left superficial groin lymph node dominant. She developed right lower limb lymphedema at approximately 4 months postoperatively and experienced cellulitis of the right lower limb twice per year.

Seven years after the initial surgery, during which the patient experienced no recurrence of cervical cancer, she underwent a checkup at our department. At that time, her right

1  
2  
3  
4  
5 limb exhibited stage 3 lymphedema whereas the left limb was not edematous.  
6 Conservative treatment for lymphedema was initiated after diagnosis.  
7  
8

## 9 10 **DISCUSSION**

11 According to previous reports, the incidence of lower limb lymphedema after  
12 gynecologic cancer resection ranges from 30% to 40%.<sup>28</sup> In addition, individual cases  
13 vary in terms of lymphedema development, elapsed time prior to edema onset, and  
14 edematous stage, even among patients who have undergone the same surgical procedure  
15 for the same type of cancer. Furthermore, although bilateral pelvic lymphadenectomy is  
16 primarily performed for patients undergoing surgical resection for gynecologic cancers,  
17 secondary lymphedema tends to develop differently in terms of both incidence and  
18 staging. These phenomena, which remain poorly understood, are thought to reflect  
19 inherent individual differences in lymphatic system function and even bilateral  
20 differences within an individual. We note that for almost all cases in our series, primary  
21 tumor resection and lymph node dissection were performed via a lower midline incision.  
22 This might have led to the formation of horizontal scars that could interrupt the flow of  
23 superficial lymph, thus accounting for some of the observed differences.  
24  
25  
26  
27  
28  
29  
30

### 31 *Limitations of this study*

32 We further note that various factors might ultimately affect lymphedema. Therefore, we  
33 examined the relationship between lymphedema laterality and staging within the same  
34 patient, rather than comparing individual cases. Despite this precaution, some problems  
35 in this study can be attributed to the retrospective design. For example, different  
36 postoperative observation periods were implemented, and we did not perform  
37 lymphoscintigraphic evaluations of lymph flow. In addition, we did not evaluate  
38 symptoms of edema by measuring changes in the limb circumference/CT volume.  
39 Finally, the time to lymphedema onset varied considerably among individuals. In future,  
40 a prospective study of patients with gynecologic cancer who have undergone pelvic  
41 lymph node dissection, including a multivariable analysis of the above-mentioned risk  
42 factors, would be of interest.  
43  
44  
45  
46  
47  
48

49 The interpretation of our study is also limited by the variability in reported CT findings.  
50 In addition, the retrospective nature precluded the detection of small lymph nodes (<5  
51 mm) or 2-dimensional measurements of lymph node size. Although we had wanted to  
52 evaluate lymphatic network function,<sup>29</sup> this parameter cannot be measured using a static  
53 imaging technique such as CT; accordingly, we instead selected a lymph node analysis.  
54 However, CT quantification of superficial groin lymph nodes might also be inaccurate,  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5 especially with regard to the actual function and flow of the nodes. Generally, deep  
6 pelvic lymph nodes such as the obturator, internal and external iliac, and para-aortic  
7 lymph nodes are resected along with primary gynecologic cancers (e.g., cervical,  
8 endometrial, and ovarian cancer). However, it is not possible to define the number of  
9 lymph nodes after surgery using the postoperative statuses of the remaining deep lymph  
10 nodes/vessels. Accordingly, in this study we indirectly examined the relationship  
11 between secondary lymphedema and superficial groin lymph nodes via horizontal plane  
12 CT evaluations. Moreover, the extent of pelvic lymphadenectomy in individual cases is  
13 affected by both the primary disease and the tumor stage, as well as differences in  
14 surgeons' skills. In the present study, we were not able to review the potential  
15 influences of these elements because of the limited number of included patients.  
16  
17  
18  
19  
20  
21

#### 22 *Relationship between superficial groin lymph nodes and secondary lymphedema*

23 The restoration of lymphatic flow can be classified roughly as a return to either a  
24 superficial lymph course, which includes the superficial groin lymph nodes, or a deep  
25 lymph course, which includes pelvic lymph nodes. We note that these courses  
26 intercommunicate in the process of lymphatic fluid drainage into the thoracic duct.<sup>25</sup>  
27

28 Therefore, as deep lymph course lymphatics are resected during pelvic  
29 lymphadenectomy, the remaining superficial groin lymph nodes are expected to play an  
30 important role in the postoperative reconstitution of lymph flow. Based on this theory,  
31 conservative treatment, including manual lymphatic drainage, is often performed for  
32 patients with secondary lymphedema in an attempt to encourage the return of superficial  
33 lymphatic flow. Similarly, most surgical procedures intended to improve lymphatic  
34 flow, such as lymphaticovenular anastomosis and lymph node transfer, are performed in  
35 the skin and subcutaneous fat tissue.<sup>30-31</sup>  
36

37 Regarding the relationship between the number of lymph nodes and lymphatic function,  
38 a larger number of lymph nodes is generally thought to permit better lymphatic flow  
39 and function.<sup>32-35</sup> In addition, larger lymph nodes are thought to provide better  
40 lymphatic flow and function. However, evaluations of lymph node size should also  
41 consider the effect of lymph node metastasis. In the present series, no superficial groin  
42 lymph nodes were affected in metastatic cases. In addition, the rate of pelvic lymph  
43 node metastasis was very low and was not thought to affect unilateral edema dominance.  
44 Although this study focused on the function of superficial groin lymph nodes after  
45 pelvic lymphadenectomy, it is clear that lymphedema development involves various  
46 complex, interconnected elements. Additional factors that may be related to  
47 lymphedema development after gynecologic tumor resection and should therefore be  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5 considered include the type of primary disease, tumor stage, presence of lymph node  
6 metastases, and lymphadenectomy. Moreover, previous studies have suggested other  
7 risk factors that might affect the development of secondary lymphedema, including age,  
8 obesity, and a history of radiation therapy. Furthermore, the present study indicates that  
9 a lack of development of superficial groin lymph nodes affects the severity of  
10 lymphedema.  
11

12  
13  
14 In the present study, patients with a large total lymph node number and/or size tended to  
15 have present with relatively earlier-stage lymphedema; in other words, superficial  
16 lymph nodes are thought to affect the onset of secondary lymphedema. Accordingly, a  
17 weak negative correlation was confirmed between the sum total superficial lymph node  
18 size and lymphedema stage. However, the lymph node number and size varied  
19 considerably among our study subjects because the groin lymph nodes were counted  
20 pre-operatively and were thus not influenced by the number of resected pelvic nodes. As  
21 a result, an inter-case of the numbers of resected pelvic lymph nodes and superficial  
22 groin lymph nodes would lack relevance.  
23  
24  
25  
26  
27

## 28 **CONCLUSIONS**

29  
30 In this study, we reviewed the relationship between superficial groin lymph node  
31 laterality and secondary lymphedema staging after primary gynecologic tumor resection  
32 with pelvic lymphadenectomy. Our results suggest that the presence of superficial groin  
33 lymph nodes affects the severity of lymphedema. However, future large-scale  
34 prospective studies are needed to determine the risk factors of patients who undergo  
35 gynecologic cancer resection and more clearly identify patients at high risk for  
36 lymphedema development.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Eva LJ, Narain S, Luesley DM. Idiopathic vulval lymphoedema. *J Obstet Gynaecol.* 2007;27(7):748-749.
2. Fujimoto N, Honda S, Nakanishi G, Tachibana T, Tanaka T. Acquired idiopathic penile lymphedema: Successful prevention of acute phase progression with low-dose corticosteroids. *J Dermatol.* 2014;41(2):157-159.
3. Hara H, Mihara M, Seki Y, Koshima I. Lymphoedema caused by idiopathic lymphatic thrombus. *J Plast Reconstr Aesthet Surg.* 2013;66(12):1780-1783.
4. Ikeda K, Ogawa Y, Kajino C, Deguchi S, Kurihara S, Tashima T, Goto W, Nishiguchi Y, Tokunaga S, Fukushima H, Inoue T. The influence of axillary reverse mapping related factors on lymphedema in breast cancer patients. *Eur J Surg Oncol.* 2014 Jul;40(7):818-23.
5. Boccardo F, Casabona F, De Cian F, Friedman D, Villa G, Bogliolo S et al. Lymphedema microsurgical preventive healing approach: A new technique for primary prevention of arm lymphedema after mastectomy. *Ann Surg Oncol.* 2009;16:703–708.
6. Beek MA, Gobardhan PD, Klompenhouwer EG, Rutten HJ, Voogd AC, Luiten EJ. Axillary reverse mapping (ARM) in clinically node positive breast cancer patients. *Eur J Surg Oncol.* 2015 Jan;41(1):59-63
7. Thompson M, Korourian S, Henry-Tillman R, Adkins L, Mumford S, Westbrook KC, Klimberg VS. Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation. *Ann Surg Oncol.* 2007 Jun;14(6):1890-5
8. Szolnoky G, Lakatos B, Keskeny T, Varga E, Varga M, Dobozy A et al. Intermittent pneumatic compression acts synergistically with manual lymphatic drainage in complex decongestive physiotherapy for breast cancer treatment-related lymphedema. *Lymphology* 2009;42: 188–194.
9. Beesley V, Janda M, Eakin E, Obermair A, Battistutta D. Lymphedema after gynecological cancer treatment: Prevalence, correlates, and supportive care needs. *Cancer* 2007; 109:2607–2614.
10. Berenji M, Kalani A, Kim J, Kelly K, Wallack MK. Massive localized lymphedema of the thigh in a morbidly obese patient. *Eur J Surg Oncol.* 2010 Jan;36(1):104-6.
11. Sukan A, Yaycioglu O, Aydin M, Yapar AF, Kizilkilic O, Reyhan M. Lymphoscintigraphic appearance of scrotal lymphatic reflux in a patient with idiopathic genital lymphedema. *Clin Nucl Med.* 2005;30(12):835-837.
12. Deng J, Ridner SH, Dietrich MS, Wells N, Wallston KA, Sinard RJ et al. Factors associated with external and internal lymphedema in patients with head-and-neck cancer. *Int J Radiat Oncol Biol Phys.* 2012 Nov 1;84(3):e319-328.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
13. Gennaro M, Maccauro M, Sigari C, Casalini P, Bedodi L, Conti AR et al. Selective axillary dissection after axillary reverse mapping to prevent breast-cancer-related lymphoedema. *Eur J Surg Oncol*. 2013 Dec;39(12):1341-5.
14. Sackey H, Magnuson A, Sandelin K, Liljegren G, Bergkvist L, Fülep Z et al. Arm lymphoedema after axillary surgery in women with invasive breast cancer. *Br J Surg*. 2014 Mar;101(4):390-7.
15. Pasko JL, Garreau J, Carl A, Ansteth M, Glissmeyer M, Johnson N. Axillary reverse lymphatic mapping reduces patient perceived incidence of lymphedema after axillary dissection in breast cancer. *Am J Surg*. 2015 May;209(5):890-5.
16. Beesley VL, Rowlands IJ, Hayes SC, Janda M, O'Rourke P, Marquart L et al. Australian National Endometrial Cancer Study Group. Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. *Gynecol Oncol*. 2015 Jan;136(1):87-93.
17. Cemal Y, Jewell S, Albornoz CR, Pusic A, Mehrara BJ. Systematic review of quality of life and patient reported outcomes in patients with oncologic related lower extremity lymphedema. *Lymphat Res Biol*. 2013 Mar;11(1):14-9.
18. Leung EY, Tirlapur SA, Meads C. The management of secondary lower limb lymphoedema in cancer patients: a systematic review. *Palliat Med*. 2015 Feb;29(2):112-9.
19. Suami H, Taylor GI, Pan WR. A new radiographic cadaver injection technique for investigating the lymphatic system. *Plast Reconstr Surg*. 2005;115:2007-2013.
20. Suami H, Taylor GI, O'Neill J, Pan WR. Refinements of the radiographic cadaver injection technique for investigating minute lymphatic vessels. *Plast Reconstr Surg*. 2007a;120:61-67.
21. Suami H, Pan WR, Taylor GI. Changes in the lymph structure of the upper limb after axillary dissection: Radiographic and anatomical study in a human cadaver. *Plast Reconstr Surg*. 2007b;120:982-991.
22. Unno N, Nishiyama M, Suzuki M, Yamamoto N, Inuzuka K, Sagara D et al. Quantitative lymph imaging for assessment of lymph function using indocyanine green fluorescence lymphography. *Eur J Vasc Endovasc Surg*. 2008;36:230-236.
23. Keo HH, Husmann M, Groechnig E, Willenberg T, Gretener SB. Diagnostic accuracy of fluorescence microlymphography for detecting limb lymphedema. *Eur J Vasc Endovasc Surg*. 2015 Apr;49(4):474-9.

- 1  
2  
3  
4  
5 24. Yamamoto T, Yoshimatsu H, Narushima M, Yamamoto N, Hayashi A, Koshima I.  
6 Indocyanine Green Lymphography Findings in Primary Leg Lymphedema. *Eur J Vasc*  
7 *Endovasc Surg.* 2015 Jan;49(1):95-102.  
8  
9  
10 25. Masachika K. Japanese lymph system anatomy (Japanese). Tokyo: *Kanahara*, 1968  
11  
12 26. Scaglioni MF, Suami H. Lymphatic anatomy of the inguinal region in aid of  
13 vascularized lymph node flap harvesting. *J Plast Reconstr Aesthet Surg.* 2015  
14 Mar;68(3):419-27.  
15  
16 27. Dayan JH, Dayan E, Kagen A, Cheng MH, Sultan M, Samson W, Smith ML. The  
17 use of magnetic resonance angiography in vascularized groin lymph node transfer: an  
18 anatomic study. *J Reconstr Microsurg.* 2014 Jan;30(1):41-5.  
19  
20 28. Todo Y, Yamamoto R, Minobe S, Suzuki Y, Takeshi U, Nakatani M et al. Okamoto  
21 K, Kato H. Risk factors for postoperative lower-extremity lymphedema in endometrial  
22 cancer survivors who had treatment including lymphadenectomy. *Gynecol Oncol.*  
23 2010;119(1):60-64.  
24  
25 29. Dayan JH, Dayan E, Smith ML. Reverse lymphatic mapping: a new technique for  
26 maximizing safety in vascularized lymph node transfer. *Plast Reconstr Surg.* 2015  
27 Jan;135(1):277-85.  
28  
29  
30 30. Onoda S, Todokoro T, Hara H, Azuma S, Goto A. Minimally invasive multiple  
31 lymphaticovenular anastomosis at the ankle for the prevention of lower leg lymphedema.  
32 *Microsurgery.* 2014;34(5):372-376.  
33  
34 31. O'Brien BM, Mellow CG, Khazanchi RK, Dvir E, Kumar V, Pederson WC.  
35 Long-term results after microlymphaticovenous anastomoses for the treatment of  
36 obstructive lymphedema. *Plast Reconstr Surg.* 1990;85:562-572.  
37  
38 32. Campisi C, Boccardo F, Zilli A, Macció A, Napoli F. The use of vein grafts in the  
39 treatment of peripheral lymphedemas: Long-term results. *Microsurgery.*  
40 2001;21:143-147.  
41  
42 33. Shahpar H, Atieh A, Maryam A, Fatemeh HS, Massoome N, Mandana E et al. Risk  
43 factors of lymph edema in breast cancer patients. *Int J Breast Cancer.*  
44 2013;2013:641818.  
45  
46 34. Ugur S, Arıcı C, Yaprak M, Mesci A, Arıcı GA, Dolay K et al. Risk factors of  
47 breast cancer-related lymphedema. *Lymphat Res Biol.* 2013;11(2):72-75.  
48  
49 35. Akita S, Mitsukawa N, Rikihisa N, Kubota Y, Omori N, Mitsuhashi A et al. Early  
50 diagnosis and risk factors for lymphedema following lymph node dissection for  
51 gynecologic cancer. *Plast Reconstr Surg.* 2013;131(2):283-90.  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure legends**

Figure 1.

Lymph node measurement using horizontal plane contrast-enhanced computed tomography, femoral bone neck level.

Bilateral superficial groin lymph nodes are elliptical (yellow circle).

Blood vessels (red arrow) are visible medial to each lymph node.

Figure 2.

Lymph node measurement using horizontal plane contrast-enhanced computed tomography, femoral bone metaphyseal level.

The left superficial groin lymph node has a rounded shape and is 8 mm in size (yellow circle).

Blood vessels (red arrow) are visible medial to each lymph node.

Figure 3.

Schema of the superficial groin lymph nodes.

All lymph nodes within the dotted line are counted.

Figure 4.

Measurement of the sizes of round lymph nodes.

Lymph node sizing was based on square dimensions, as shown.

Figure 5.

Measurement of the sizes of elliptical lymph nodes.

Lymph node sizes were determined using the mean major and mean minor dimensions, as shown.

Figure 6.

Scatter plot analysis of the relationship between the sum total size of the superficial groin lymph nodes and the stage of lymphedema.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1.  
Lymph node measurement using horizontal plane contrast-enhanced computed tomography, femoral bone neck level.  
Bilateral superficial groin lymph nodes are elliptical (yellow circle).  
Blood vessels (red arrow) are visible medial to each lymph node.

165x97mm (300 x 300 DPI)

Review




Figure 2.

Lymph node measurement using horizontal plane contrast-enhanced computed tomography, femoral bone metaphyseal level.

The left superficial groin lymph node has a rounded shape and is 8 mm in size (yellow circle).  
Blood vessels (red arrow) are visible medial to each lymph node.

167x100mm (300 x 300 DPI)

Review



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3.  
Schema of the superficial groin lymph nodes.  
All lymph nodes within the dotted line are counted.

304x376mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 4.  
Measurement of the sizes of round lymph nodes.  
Lymph node sizing was based on square dimensions, as shown.

135x135mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 5.  
Measurement of the sizes of elliptical lymph nodes.  
Lymph node sizes were determined using the mean major and mean minor dimensions, as shown.

135x135mm (300 x 300 DPI)




Figure 6.  
Scatter plot analysis of the relationship between the sum total size of the superficial groin lymph nodes and the stage of lymphedema.

489x280mm (300 x 300 DPI)

Table.1 Patient Treatment History

No.	Age	Primary Disease	Ca. Stage	LE Stage		CT	RT	Follow up time
				Right	Left			
1	68	Cervical ca.	2B	3	0	—	+	5M
2	31	Cervical ca.	2B	2L	1	+	+	1Y
3	33	Cervical ca.	1B	2L	1	—	—	5Y
4	59	Cervical ca.	2B	2L	1	+	+	7M
5	65	Cervical ca.	1B	2L	0	+	+	6M
6	51	Endometrial ca.	1C	2L	0	+	—	2M
		+ Ovarian ca	+ 1B					
7	67	Endometrial ca.	1B	2	1	+	+	1Y 6M
8	63	Endometrial ca.	1B	2	0	+	—	6M
9	69	Endometrial ca.	2B	2	0	+	+	3M
10	60	Endometrial ca.	1B	1	0	+	—	7Y 8M
11	74	Endometrial ca.	1C	1	0	+	—	6Y 6M
12	71	Endometrial ca.	1C	1	0	—	—	3M
13	50	Cervical ca.	1B	1	0	+	+	1M
14	40	Cervical ca.	2B	1	0	—	+	1M
15	32	Endometrial ca.	3C	1	0	—	—	1M
16	42	Cervical ca.	1B	1	0	+	+	3M
17	49	Cervical ca.	1B	0	1	—	+	5Y
18	76	Endometrial ca.	1C	0	1	+	—	1M
19	39	Cervical ca.	2B	0	1	+	+	1M
20	65	Endometrial ca.	1B	0	2	+	+	6M
21	45	Cervical ca.	1B	0	2	+	—	1M
22	61	Cervical ca.	1B	1	2	+	+	6M
23	67	Cervical ca.	1B	0	2L	+	—	1M
24	57	Cervical ca.	1B	1	2L	—	+	1M
25	37	Cervical ca.	1B	1	2L	—	+	8M

ca.: carcinoma, LE: lymphedema, 2L: late stage 2, CT: chemotherapy, RT: radiation therapy, Follow up time: follow-up time from initial resection to lymphedema development, Y: year, M: month

Table 2  
Relationship between lymphedema stages and each lymph nodes

No.	Age	Primary Disease	LE Stage		PLN and positive rate		Number and Size (mm) of superficial groin lymph nodes	
			Right	Left	Right	Left	Right	Left
<b>Right Side Edema Dominant Cases</b>								
1	68	Cervical ca.	3	0	1/23	0/17	2: 7, 8	5: 7, 8, 8,9, 10
2	31	Cervical ca.	2L	1	1/25	0/20	4: 7, 9, 9, 11	7: 6, 6, 7, 9, 9, 10, 12
3	33	Cervical ca.	2L	1	0/17	0/14	1: 6	1: 8
4	59	Cervical ca.	2L	1	0/23	0/11	3: 6, 7, 9	4: 8, 8, 9, 10
5	65	Cervical ca.	2L	0	1/13	2/17	2: 6, 7	2: 7, 7
6	51	Endometrial ca. +Ovarian ca	2L	0	0/46	0/21	2: 6, 8	3: 6, 8, 9
7	67	Endometrial ca.	2	1	0/14	0/10	1: 12	3: 9, 9, 11
8	63	Endometrial ca.	2	0	0/18	0/13	4: 5, 5, 6, 9	5: 6, 6, 6, 8, 9
9	69	Endometrial ca.	2	0	1/26	0/15	2: 6, 9	2: 6, 9
10	60	Endometrial ca.	1	0	0/11	0/31	2: 8, 10	3: 7, 9, 10
11	74	Endometrial ca.	1	0	0/29	0/15	1: 9	3: 6, 8, 9
12	71	Endometrial ca.	1	0	0/14	0/9	2: 6, 6	5: 6, 7, 7, 7, 8
13	50	Cervical ca.	1	0	0/23	0/24	1: 6	2: 7, 8
14	40	Cervical ca.	1	0	6/24	7/26	3: 6, 8, 9	4: 6, 8, 8, 9
15	32	Endometrial ca.	1	0	0/40	2/23	2: 5, 5	2: 7, 9
16	42	Cervical ca.	1	0	0/17	2/16	2: 6, 9	4: 5, 6, 6, 9
<b>Left Side Edema Dominant Cases</b>								
17	49	Cervical ca.	0	1	0/9	0/23	3: 6, 6, 7	3: 6, 6, 7
18	76	Endometrial ca.	0	1	0/7	0/7	2: 8, 11	1: 5
19	39	Cervical ca.	0	1	4/15	2/21	3: 5, 7, 9	4: 7, 7, 8, 10
20	65	Endometrial ca.	0	2	0/11	0/14	2: 7, 9	1: 9
21	45	Cervical ca.	0	2	1/15	3/29	4: 6, 7, 8, 9	3: 7, 7, 9
22	61	Cervical ca.	1	2	0/6	1/7	2: 10, 12	1: 12
23	67	Cervical ca.	0	2L	0/13	0/11	5: 7, 8, 9, 10, 10	4: 5, 6, 8, 10
24	57	Cervical ca.	1	2L	0/14	0/14	2: 9, 11	1: 12
25	37	Cervical ca.	1	2L	0/10	0/20	4: 5, 5, 7, 7	2: 5, 9

LE: lymphedema, PLN and positive rate : pelvic lymph nodes resected at surgery and

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

metastatic positive rate

For Peer Review



Table.3 International Society of Lymphology (ISL) lymphedema staging

<b>ISL stage 0</b>	A subclinical state where swelling is not evident despite impaired lymph transport. This stage may exist for months or years before edema becomes evident.
<b>ISL stage I</b>	This represents early onset of the condition where there is accumulation of tissue fluid that subsides with limb elevation. The edema may be pitting at this stage.
<b>ISL stage II</b>	Limb elevation alone rarely reduces swelling and pitting is manifest.
<b>ISL late stage II</b>	There may or may not be pitting as tissue fibrosis is more evident.
<b>ISL stage III</b>	The tissue is hard (fibrotic), and pitting is absent. Skin changes such as thickening, hyperpigmentation, increased skin folds, fat deposits, and warty overgrowths develop.